Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential

被引：6

作者：

Xu, Jingjing ^{[1
,2
]}

Jiang, Xiaohua ^{[2
]}

Xu, Suowen ^{[1
]}

机构：

[1] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Endocrinol, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China

[2] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Obstet & Gynecol, Hefei 230001, Anhui, Peoples R China

来源：

DRUG DISCOVERY TODAY | 2023年 / 28卷 / 11期

基金：

中国国家自然科学基金;

关键词：

aprocitentan; endothelin-1; hypertension; resistant hypertension; JAPANESE PATIENTS; BOSENTAN; MACITENTAN; SAFETY; TOLERABILITY; PHARMACOLOGY; EXPRESSION; DISEASES; MIRNA-1;

D O I：

10.1016/j.drudis.2023.103788

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypertension is reaching epidemic proportions worldwide and is a significant public health concern. However, -15% of patients with hypertension continue to experience elevated blood pressure, even after taking antihypertensive medications [such as angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), dihydropyridine calcium channel blockers (CCBs) and thiazide diuretics], a condition referred to as resistant hypertension (RH). Within the complex realm of blood pressure regulation and vascular function, endothelin-1 (ET-1), a potent vasoconstrictor, plays a pivotal role. Recent research, particularly a Phase III clinical trial (NCT03541174), has shed light on the potential of aprocitentan, a dual ET-1 receptor antagonist, in significantly lowering blood pressure in individuals with RH. In this review, we summarize the mechanism of action and therapeutic potential of aprocitentan as an innovative approach for treating RH.

引用

页数：10

共 50 条

[21] CHARACTERIZATION AND LOCALIZATION OF ENDOTHELIN-1 (ET-1) RECEPTORS IN THE PROSTATE
KOBAYASHI, S
TANG, R
WANG, B
SHAPIRO, E
LEPOR, H
[J]. FASEB JOURNAL, 1993, 7 (03): : A34 - A34
[22] Reduced catabolism of endothelin-1 (ET-1) by hepatocytes - A mechanism of increased circulating and hepatic levels of ET-1 in liver cirrhosis.
Gandhi, CR
Kuddus, R
[J]. FASEB JOURNAL, 1999, 13 (05): : A1029 - A1029
[23] Lack of augmented hypoxic pulmonary hypertension in mice overexpressing human endothelin-1 (ET-1)
Fagan, KA
Hocher, B
Theuring, F
Rodman, DM
[J]. FASEB JOURNAL, 2000, 14 (04): : A126 - A126
[24] BQ-610, AN ENDOTHELIN-1 (ET-1) ANTAGONIST, CAUSES PULMONARY VASOCONSTRICTION IN NEWBORN PIGLETS
KUMAR, P
KONDURI, GG
[J]. PEDIATRIC RESEARCH, 1994, 35 (04) : A85 - A85
[25] INHIBITION OF ENDOTHELIN-1 (ET-1) BY THE DUAL RECEPTOR ANTAGONIST, BOSENTAN, INCREASES MMP-9 EXPRESSION BY SCLERODERMIC FIBROBLASTS IN VITRO
Iannone, F.
Bizzoca, R.
Chiala, A.
Lanciano, E.
Lapadula, G.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S104 - S104
[26] ENDOTHELIN-B-RECEPTOR (ETB) MEDIATES AUTOINDUCTION OF ENDOTHELIN-1 (ET-1)
IWASAKI, S
HOMMA, T
KON, V
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 717 - 717
[27] CENTRAL EFFECT OF ENDOTHELIN-1 (ET-1) AND ENDOTHELIN-3 (ET-3) IN MICE
MASLAROVA, J
GETOVA, D
SEMKOVA, I
NIKOLOV, R
[J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1995, 17 (07): : 431 - 436
[28] EFFECTS OF ENDOTHELIN-1 (ET-1) AND ENDOTHELIN-3 (ET-3) ON CONVULSIVE SEIZURES
GETOVA, DP
MASLAROVA, JE
NIKOLOV, RK
SEMKOVA, IS
[J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1994, 16 (03): : 173 - 178
[29] Influence of Endothelin-1 (ET-1) and an ET-1 Receptor Blockade on endothelial Micro Particles in vitro and in vivo
Jung, C.
Lichtenauer, M.
Wernly, B. D.
Franz, M.
Fritzenwanger, M.
Goebel, Bjoern
Edlinger, C.
Rafnsson, A.
Figulla, H. -R.
Pernow, J.
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S303 - S304
[30] CENTRAL MODULATION OF CARDIAC-OUTPUT BY ENDOTHELIN-1 (ET-1)
HEMATILLAKE, G
LAHANN, TR
[J]. FASEB JOURNAL, 1992, 6 (04): : A1531 - A1531

← 1 2 3 4 5 →